

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/P83F03BD8EFEN.html>

Date: August 2019

Pages: 61

Price: US\$ 3,500.00 (Single User License)

ID: P83F03BD8EFEN

Abstracts

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

The report 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 3 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Respiratory, Women's Health, Dermatology and Ophthalmology which include indications Chronic Cough, Pain, Neuropathic Pain (Neuralgia), Visceral Pain, Endometriosis, Inflammatory Pain, Alzheimer's Disease, Cough, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain and Pruritus.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)

The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects

The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

P2X Purinoceptor 3 (P2RX3) - Overview

P2X Purinoceptor 3 (P2RX3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development

Bayer AG

Beijing Tide Pharmaceutical Co Ltd

Integral Molecular Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Ossianix Inc

Pfizer Inc

Shionogi & Co Ltd

P2X Purinoceptor 3 (P2RX3) - Drug Profiles

BAY-1817080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1902607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-300 Backups - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-600918 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 Receptor for Chronic Pain and Neuropathic Pain -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X3 for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 3 (P2RX3) - Dormant Products

P2X Purinoceptor 3 (P2RX3) - Discontinued Products

P2X Purinoceptor 3 (P2RX3) - Product Development Milestones

Featured News & Press Releases

Aug 26, 2019: BELLUS Health strengthens leadership team with appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer

Jul 31, 2019: Bellus Health starts recruitment in Phase II chronic cough trial

Jul 25, 2019: Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)

Jul 25, 2019: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough

Jul 15, 2019: BELLUS Health convenes KOL meeting to discuss the state of chronic cough treatment

May 21, 2019: BELLUS Health presents Phase 1 data for BLU-5937, its lead product candidate for the treatment of refractory chronic cough, at the American Thoracic Society International Conference

May 15, 2019: BELLUS Health to present at three upcoming healthcare investor conferences

May 08, 2019: BELLUS Health provides update on its chronic cough drug candidate BLU-5937

Apr 04, 2019: BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences

Apr 03, 2019: BELLUS Health announces clearance of U.S. IND for BLU-5937 phase 2 study in chronic cough patients

Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate

Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018

Oct 31, 2018: Bellus health announces issuance of new U.S. patent claiming P2X3 selectivity as a means of minimizing taste effects for its lead chronic cough drug candidate BLU-5937

Sep 25, 2018: BELLUS Health announces appointment of clinical advisory board

Jul 19, 2018: BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Beijing Tide Pharmaceutical Co Ltd, H2 2019
Pipeline by Integral Molecular Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Pipeline by Ossianix Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Shionogi & Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Bayer AG

Beijing Tide Pharmaceutical Co Ltd

Integral Molecular Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Ossianix Inc

Pfizer Inc

Shionogi & Co Ltd

I would like to order

Product name: P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/P83F03BD8EFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P83F03BD8EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970